Article

Global Access Program - HIV

Working hand in hand - Providing innovative HIV/AIDS diagnostic solutions to those you need it most

More than 35 million people are currently living with HIV

Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organizations have joined together with an ambitious goal: ending the HIV/AIDS pandemic.

As the leading provider of HIV viral load testing, Roche created the Global Access Program to contribute to the UNAIDS 90-90-90 goal, expanding access to quality, sustainable diagnostic testing for countries hardest hit by HIV.

We applaud all the global partners who came together to ensure that over 31 million people living with HIV/AIDS in low- and middle-income countries will be able to access viral load testing at this reduced price.

President Bill Clinton, Chairman of the Clinton Health Access Initiative

We welcome this significant price breakthrough – the urgent call of people living with HIV is being answered. Now, with viral load testing, we can help ensure HIV treatment improves quality of life.

Michel Sidibé, Former UNAIDS Executive Director

Break down lab barriers with integrated and automated slide stainer instrumentation

Optimize and grow your business with Roche's automated slide staining systems. Our comprehensive portfolio streamlines the processes of a wide range of diagnostic needs, including:

Routine hemotoxylin and eosin (H&E) staining: The VENTANA® HE 600 system automates the entire H&E staining process, freeing up valuable lab personnel time while minimizing manual errors.
Special stains: The BenchMark Special Stains system automates workflows, enhancing consistency and efficiency in identifying specific tissue features.
Immunohistochemistry (IHC) and in-situ hybridization (ISH): The BenchMark GX, BenchMark ULTRA, and BenchMark ULTRA PLUS systems offer a range of solutions for IHC and ISH testing

Automated solutions reduce technician time, maximize throughput, and enhance turnaround times while ensuring the right patient gets the right stain each and every time. These automated slide staining systems help create consistent and reproducible results.

At Roche, we believe every patient deserves individual attention. Our staining systems perform individual slide staining, producing personalized, high-quality slides, while mitigating the risk of cross-contamination.

Our vision is for patients worldwide to access quality testing that is automated, consistent, and reproducible in any laboratory.

Innovation in HIV testing

cobas^® Plasma Separation Card

Redefine the reach of reliable testing. Making quantitative HIV viral load testing more accessible to those in remote areas.¹

View now

Explore

Watch the videos

Take aim at HIV

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Take aim at HIV

Uncover the impact of accessible HIV diagnostics.

An innovative approach

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

An innovative approach

Dried plasma spot testing makes reliable HIV diagnostics more accessible than ever.

Our efforts in motion

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Our efforts in motion

The Global Access Program is aiming to make a measurable impact on global HIV numbers.

...

95-95-95 lays the groundwork for achieving global HIV viral suppression. By 2030...

95%

of people living with HIV will know their HIV status

95%

of people who know their status recieve treatment

95%

of people on HIV treatment have a surpressed viral load

95-95-95 aims to put an end to the AIDS epidemic by 2030.²

Targeting 95-95-95 with optimized diagnostic testing

The Global Access Program contributes to the goals of 95-95-95 by providing diagnostic products for early infant diagnosis and viral load testing.

Early Infant Diagnosis

Early diagnosis in infants and young children is a major challenge—antibody tests are ineffective due to maternal antibodies remaining in the child. The Roche HIV-1/HIV-2 Qualitative Assay provides reliable, accurate information on whether or not an infant is infected.³

Dry blood spot

The use of dried blood spots is an increasingly sustainable solution which allows for PCR testing. Collecting a small blood sample on a specially designed collection card facilitates easy sample transportation and storage, and is ideal for resource-limited areas.³

The number of children younger than 15 recieving life-saving antiretroviral therapy (ART) gloally increased from 435,000 in 2010 to 948,000 in 2019.⁴

85% of pregnant women living with HIV had access to antiretroviral medicines to prevent transmission of HIV to their child in 2019.⁵

Expansion of Prevent-Mother-toChild Transmission (PMTCT) programs have helped avoid approximately 1.4 million new HIV infections among children between 2010 and 2018. ⁶

From 2010 to 2016 the number of children aged 0-14 years dying of AIDS-related illnesses was nearly cut in half in just six years.⁷

Learn more about the critical importance of early infant diagnosis.

Download Brochure

Viral Load Testing

Roche is a global market leader in HIV viral load testing, a method for determining the amount of HIV circulating in a body. Testing for viral load can confirm if patients are responding to medication, or if second-line therapies should be considered.

40-fold

increase in access to antiretroviral therapy since 2002.⁸

33% decrease

in new HIV infections since 2001.⁸

Additional Global Access Program HIV Information

90-90-90

Diagnostics Access Initiative

Case Study: Clinton Health Access Initiative

Our partners

UNAIDS

UNAIDS is working to end the AIDS epidemic by 2030.

Clinton Health Access Initiative

CHAI was founded to help the lives of millions of people living with HIV/AIDS in the developing world.

The Global Fund

Accelerating the end of AIDS, tuberculosis, and malaria as epidemics.

References

Carmona S, Seiverth B, Magubane D. Separation of plasma from whole blood by use of the cobas plasma separation card: a compelling alternative to dried blood spots for quantification of HIV-1 viral load. https://jcm.asm.org/content/57/4/e01336-18/article-info. Accessed 24 Oct 2023.
Understanding Fast-Track. Accelerating Action to End the AIDS Epidemic by 2030. UNAIDS. https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf. Accessed 24 Oct 2023.
Mazanderani AH, Moyo F,Kufa T et al. Differentiating clearly positive from intermediate results: A review of irreducible HIV-1 PCR positive samples from South Africa’s early infant diagnostic program, 2010-2015. Diagnostic Microbiol and Infectious disease. 018. 91;3:248-255. https://www.sciencedirect.com/science/article/pii/S0732889318300786. Accessed 24 Oct 2023.
https://data.unicef.org/wp-content/uploads/2019/07/HIV_Paediatric_ART_Coverage_2020.xlsx. Accessed 24 Oct 2023.
https://www.unaids.org/en/resources/fact-sheet. Accessed 24 Oct 2023.
https://www.avert.org/professionals/hiv-programming/prevention/prevention-mother-child. Accessed 24 Oct 2023.
UNAIDS. 2023 Global AIDS Update. The path that ends AIDS. https://www.unaids.org/sites/default/files/media_asset/2023-unaids-global-aids-update-summary_en.pdf. Accessed 24 Oct 2023.
UNAIDS 2013 | AIDS by the numbers. www.unaids.org/sites/default/files/media_asset/JC2571_AIDS_by_the_numbers_en_1.pdf. Accessed 24 Oct 2023.

User Profile

Select your user profile

Innovation in HIV testing